Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

N/AActive Not RecruitingNCT05368207

University Health Network, Toronto1 enrolled

Overview

This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Small Cell Carcinoma, Hypercalcaemic Type Ovarian Cancer

Interventions

PembrolizumabDRUG

Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) Exclusion Criteria: * N/A

Locations (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Progression free survival

Determined by CT scans

Time frame: 2 years

Secondary Outcomes

overall performance status

Eastern cooperative oncology group (ECOG) score, patient-reported symptoms as well as objective measurements by CT scans.

Time frame: 2 years

Objective evidence of response to treatment

Recorded with CA-125 every 6 weeks and CT scans after every 2 cycles of treatment

Time frame: 2 years

Exploratory Endpoint

Exploratory Endpoint will be measured by circulating DNA to monitor minimal residual disease

Time frame: 2 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.